- Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
-
Kim YS
- KMID: 2521598
- Intest Res.
- 2021 Oct;19(4):357-359.
- doi: 10.5217/ir.2021.00120
-
- CITED
-
- Close
- SHARE
-
- Close
- Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
-
Cicero G, Mazziotti S
- KMID: 2521600
- Intest Res.
- 2021 Oct;19(4):365-378.
- doi: 10.5217/ir.2020.00097
Over recent years, inflammatory bowel diseases have become an issue of increased attention in daily clinical practice, due to both a rising incidence and improved imaging capability in detection. In... -
- CITED
-
- Close
- SHARE
-
- Close
- An elderly woman with severe enteritis mimicking infectious enteritis
-
Nagashima K, Kato T, Kimura T, Kishi K, Baba U
- KMID: 2521613
- Intest Res.
- 2021 Oct;19(4):482-484.
- doi: 10.5217/ir.2020.00038
-
- CITED
-
- Close
- SHARE
-
- Close
- Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
-
Park J, Kim DH, Kim S, Ma HW, Park IS, Son M, Kim JH, Shin Y, Kim SW, Cheon JH
- KMID: 2521612
- Intest Res.
- 2021 Oct;19(4):478-481.
- doi: 10.5217/ir.2021.00121
-
- CITED
-
- Close
- SHARE
-
- Close
- Gut microbiome and checkpoint inhibitor colitis
-
Sehgal K, Khanna S
- KMID: 2521599
- Intest Res.
- 2021 Oct;19(4):360-364.
- doi: 10.5217/ir.2020.00116
Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival.... -
- CITED
-
- Close
- SHARE
-
- Close
- Hydroxyurea associated ileocecal valve ulcer: evidence for causality
-
Jayaraman T, Rajaram RB, Gan GG, Hilmi I
- KMID: 2521610
- Intest Res.
- 2021 Oct;19(4):468-471.
- doi: 10.5217/ir.2020.00099
Hydroxyurea is an antimetabolite drug that is commonly used in many hematological disorders. Ulcer formation in the gastrointestinal tract is a rare phenomenon associated with this drug. We report a... -
- CITED
-
- Close
- SHARE
-
- Close
- Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
-
Kim ES, Park JH, Choe YH, Kim MJ
- KMID: 2521611
- Intest Res.
- 2021 Oct;19(4):472-477.
- doi: 10.5217/ir.2020.00072
Crohn’s disease (CD) presenting as gastric outlet obstruction is rare but serious clinical presentation of CD causing severe morbidity. However, there have been few case reports concerning this disorder in... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
-
Hayashi R, Ueno Y, Tanaka S, Onishi K, Takasago T, Wakai M, Naito T, Sasaki K, Doi S, Masaki T, Chayama K
- KMID: 2521606
- Intest Res.
- 2021 Oct;19(4):430-437.
- doi: 10.5217/ir.2020.00067
Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal... -
- CITED
-
- Close
- SHARE
-
- Close
- An overview of the gut side of the SARS-CoV-2 infection
-
Barbosa da Luz B, de Oliveira NMT, França dos Santos IW, Paza LZ, Braga LLVdM, Platner FdS, Werner MFdP, Fernandes ES, Maria-Ferreira D
- KMID: 2521601
- Intest Res.
- 2021 Oct;19(4):379-385.
- doi: 10.5217/ir.2020.00087
In late 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated in Wuhan, Hubei province, China. The major clinical symptoms described for coronavirus disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
-
Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T
- KMID: 2521605
- Intest Res.
- 2021 Oct;19(4):419-429.
- doi: 10.5217/ir.2020.00033
Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan.... -
- CITED
-
- Close
- SHARE
-
- Close
- Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
-
Banerjee R, Pal P, Nabi Z, Shava U, Ganesh G, Reddy DN
- KMID: 2521603
- Intest Res.
- 2021 Oct;19(4):398-407.
- doi: 10.5217/ir.2020.00107
Background/Aims: Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
-
Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T
- KMID: 2521604
- Intest Res.
- 2021 Oct;19(4):408-418.
- doi: 10.5217/ir.2020.00025
Background/Aims: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up... -
- CITED
-
- Close
- SHARE
-
- Close
- Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
-
Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Legaki E, Gazouli M, Koutroubakis IE
- KMID: 2521609
- Intest Res.
- 2021 Oct;19(4):461-467.
- doi: 10.5217/ir.2020.00042
Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
-
Hisamatsu T, Kim HJ, Motoya S, Suzuki Y, Ohnishi Y, Fujii N, Matsushima N, Zheng R, Marano CW
- KMID: 2521602
- Intest Res.
- 2021 Oct;19(4):386-397.
- doi: 10.5217/ir.2020.00080
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
-
Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T
- KMID: 2521608
- Intest Res.
- 2021 Oct;19(4):448-460.
- doi: 10.5217/ir.2020.00026
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
-
Jain S, Namdeo D, Sahu P, Kedia S, Sahni P, Das P, Sharma R, Gupta V, Makharia G, Dar L, Travis SP, Ahuja V
- KMID: 2521607
- Intest Res.
- 2021 Oct;19(4):438-447.
- doi: 10.5217/ir.2020.00055
Background/Aims: Predictors of short-term outcome of intravenous (IV) steroid therapy in acute severe ulcerative colitis (ASUC) have been well described, but the impact of cytomegalovirus (CMV) infection as a predictor... -
- CITED
-
- Close
- SHARE
-
- Close
